Illustrative image – not actual.Corona Remedies, a Gujarat-based pharmaceutical company, has inaugurated and commercialised a dedicated EU-GMP approved women’s hormone manufacturing facility at Bhayla near Ahmedabad.
The integrated unit, spread across one lakh sq. ft. is designed to serve both domestic and international requirements and marks the completion of a strategic shift in the company’s manufacturing base. The plant has an annual production capacity of 194 million tablets and capsules, along with 1.5 million ointments and gels, significantly enhancing the company’s in-house hormone manufacturing capability by nearly 20 percent. It is equipped with fully integrated closed-loop systems, 21 CFR-compliant equipment, and Quality by Design (QbD) principles to ensure high-quality pharmaceutical production. The facility also features advanced gelatin processing systems, precision-controlled agitation, jacketed vessels, and real-time online process monitoring to improve formulation consistency and batch-to-batch reproducibility.
With its advanced infrastructure and compliance standards, the plant strengthens Corona Remedies’ position in the women’s hormone therapy segment while expanding its manufacturing capabilities for global pharmaceutical markets.
